BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

BioCentury, like the biomedical innovation ecosystem it serves, is relentlessly focused on the future, but the turn of a decade is a good time to check in on the progress industry has made possible --...
BC Extra | Dec 2, 2019
Company News

Dec. 2 Regulatory Roundup: Chipscreen’s approval; plus Priority Review for new Imfinzi, Keytruda indications; EMA reviewing Orchard, Amarin candidates; and more

A spate of regulatory news since the start of the Thanksgiving holiday included a drug approval for Chipscreen, a duo of Priority Reviews from FDA, a pair of EMA reviews, and the scheduling of two...
BC Extra | Sep 10, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

Sanofi to pay Lexicon $260M as Zynquista ends  Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million up front plus $52 million over the next 12 months as part of the companies’ agreement to...
BioCentury | Aug 31, 2019
Product Development

Back to School 2019: Rules of the road for digital health

There is a moment, just as a new technological wave starts to swell, when those creating the platform and those who will be affected by it can come together to shape its future. This moment...
BC Extra | Aug 9, 2019
Clinical News

Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert

Biomarker data lift Lexicon   Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) rose $0.25 (20%) to $1.53 Friday after reporting pooled 52-week follow-up data from two Phase III trials showing that Zynquista sotagliflozin lowered biomarker levels of chronic...
BC Extra | Jul 26, 2019
Company News

July 26 Company Quick Takes: Lexicon hit by Phase III miss, scuttled deal; plus Xeljanz, Shield, Galapagos, Amarin and more

Sanofi canceling diabetes deal following Phase III misses Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) dropped $2.79 (49%) to $2.90 in after-hours trading Friday after Sanofi (Euronext:SAN; NASDAQ:SNY) said it would terminate the partners’ collaboration on Zynquista sotagliflozin...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Extra | Apr 29, 2019
Company News

April 29 Quick Takes: Takeda, Emendo, ViiV, Zynquista, Benlysta and more

Takeda considering value-based pricing in EU  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) is mulling employing a value-based pricing model in Europe for Alofisel darvadstrocel, a stem cell therapy to treat complex perianal fistulas in patients...
BC Extra | Apr 11, 2019
Politics & Policy

Regulatory reprieve with Brexit delay

An EU-granted extension for Brexit means short-term clarity for biopharma companies expecting EMA or European Commission decisions before the new Oct. 31 deadline. The U.K. had been scheduled to leave the union Friday. At least...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
Items per page:
1 - 10 of 523
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

BioCentury, like the biomedical innovation ecosystem it serves, is relentlessly focused on the future, but the turn of a decade is a good time to check in on the progress industry has made possible --...
BC Extra | Dec 2, 2019
Company News

Dec. 2 Regulatory Roundup: Chipscreen’s approval; plus Priority Review for new Imfinzi, Keytruda indications; EMA reviewing Orchard, Amarin candidates; and more

A spate of regulatory news since the start of the Thanksgiving holiday included a drug approval for Chipscreen, a duo of Priority Reviews from FDA, a pair of EMA reviews, and the scheduling of two...
BC Extra | Sep 10, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

Sanofi to pay Lexicon $260M as Zynquista ends  Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million up front plus $52 million over the next 12 months as part of the companies’ agreement to...
BioCentury | Aug 31, 2019
Product Development

Back to School 2019: Rules of the road for digital health

There is a moment, just as a new technological wave starts to swell, when those creating the platform and those who will be affected by it can come together to shape its future. This moment...
BC Extra | Aug 9, 2019
Clinical News

Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert

Biomarker data lift Lexicon   Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) rose $0.25 (20%) to $1.53 Friday after reporting pooled 52-week follow-up data from two Phase III trials showing that Zynquista sotagliflozin lowered biomarker levels of chronic...
BC Extra | Jul 26, 2019
Company News

July 26 Company Quick Takes: Lexicon hit by Phase III miss, scuttled deal; plus Xeljanz, Shield, Galapagos, Amarin and more

Sanofi canceling diabetes deal following Phase III misses Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) dropped $2.79 (49%) to $2.90 in after-hours trading Friday after Sanofi (Euronext:SAN; NASDAQ:SNY) said it would terminate the partners’ collaboration on Zynquista sotagliflozin...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Extra | Apr 29, 2019
Company News

April 29 Quick Takes: Takeda, Emendo, ViiV, Zynquista, Benlysta and more

Takeda considering value-based pricing in EU  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) is mulling employing a value-based pricing model in Europe for Alofisel darvadstrocel, a stem cell therapy to treat complex perianal fistulas in patients...
BC Extra | Apr 11, 2019
Politics & Policy

Regulatory reprieve with Brexit delay

An EU-granted extension for Brexit means short-term clarity for biopharma companies expecting EMA or European Commission decisions before the new Oct. 31 deadline. The U.K. had been scheduled to leave the union Friday. At least...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
Items per page:
1 - 10 of 523